SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is seeing intense community speculation as investors debate whether the asset is primed for a massive short squeeze or experiencing a cycle of recurring pump-and-dump activity. Traders are actively tracking volume spikes and social sentiment while closely monitoring technical levels for signs of a potential sustained breakout.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is attracting significant interest due to its pending merger with Agility Robotics, a move that has sparked intense debate over whether it represents a transformative investment or a classic SPAC pump-and-dump scheme. While proponents highlight the company's high-profile backing from heavyweights like Amazon and Nvidia, skeptics are questioning the lack of tangible industrial sales and the inherent risks associated with the post-merger valuation model.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin (XCN) is currently trending as investors focus on the upcoming launch of the Goliath mainnet, with the community actively debating whether the rollout will serve as a major catalyst for long-term institutional adoption or result in another "sell the news" price drop. While some investors are aggressively accumulating and highlighting the protocol's high-speed, compliant infrastructure, skeptics remain vocal, labeling the project a liquidity-focused scheme and warning others about historical volatility and lack of transparent partnerships.

Oatly Group AB is a holding company, which focuses on developing expertise around oats, a global power crop with inherent properties suited for sustainability and human health. It operates through the following geographical segments: Europe & International, North America and Greater China. The company was founded by Björn Öste in 1994 and is headquartered in Malmö, Sweden.

Oatly Group AB - ADR

Oatly Group

Oatly is currently a major focus for investors as the community eagerly awaits a potential China carve-out to stabilize the balance sheet and bolster liquidity. Despite concerns over debt and share price performance, there is significant enthusiasm surrounding the company's expansion into new product categories like matcha and cold foam, which many hope will drive the next wave of profitable growth.

Freeport-McMoRan, Inc. engages in the mining of copper, gold, and molybdenum. It operates through the following segments: U.S. Copper Mines, South America Operations, Indonesia Operations, Molybdenum Mines, U.S. Rod and Refining, Atlantic Copper, and Corporate and Other. The U.S. Copper Mines segment operates open-pit copper mines in Morenci, Bagdad, Safford, Sierrita, Miami in Arizona and Chino, and Tyrone in New Mexico. The South America Operations segment includes Cerro Verde in Peru and El Abra in Chile. The Indonesia Operations segment handles the operations of the Grasberg minerals district that produce copper concentrate containing significant quantities of gold and silver. The Molybdenum Mines segment includes the Henderson underground mine and Climax open pit mine, both in Colorado. The U.S. Rod and Refining segment consists of copper conversion facilities located in North America and includes refinery and rod mills. The Atlantic Copper segment smelts and refines copper concentrate and markets refined copper and precious metals in slimes. The Corporate and Other segment offers other mining and eliminations, oil and gas operations, and other corporate and elimination items. The company was founded by James R. Moffett on November 10, 1987, and is headquartered in Phoenix, AZ.

Freeport-McMoRan Inc

Freeport-McMoRan is trending as investors weigh its role as a primary beneficiary of the long-term copper supercycle driven by AI data center expansion and electrification demand. While community discourse acknowledges persistent production challenges at Grasberg, sentiment remains anchored to the company's status as a top-tier producer positioned to capitalize on structural global supply deficits.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is trending as investors show renewed interest following positive clinical updates for its oncology and cardiovascular pipeline, including trial results for Camzyos and label expansions for Breyanzi. The community is actively discussing the stock's potential for a long-term turnaround, focusing on its ability to mitigate future patent cliffs through strategic R&D investments and steady dividend payouts.

Bill Holdings, Inc. engages in the provision of cloud-based software solutions. The firm simplifies, digitizes, and automates complex back-office financial operations for small and midsize businesses. Its software helps customers generate and process invoices, streamline approvals, send and receive payments, sync with their accounting systems and manage their cash. The company was founded by Rene Lacertea in April 2006 and is headquartered in San Jose, CA.

BILL Holdings Inc

Bill.com Holdings Inc

Bill Holdings is under significant scrutiny as activist investors, including Starboard Value and Elliott Investment Management, push for a potential sale or strategic shift. Community sentiment remains polarized, with many investors frustrated by the stock's persistent decline while simultaneously speculating that a buyout at a premium is inevitable given the company's solid balance sheet and depressed valuation.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is trending as the market evaluates its competitive positioning in the weight-loss drug race with MariTide and tracks regulatory developments surrounding its portfolio. Investors are closely monitoring its performance against sector peers and active M&A discussions while navigating a broader rotation within the healthcare sector.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as the community debates the project's long-term viability following a leadership transition and persistent downward price action. While some investors remain committed to the long-term utility of Flexa's payment rails and potential regulatory milestones, others are vocal about their frustration regarding lack of communication and significant portfolio losses.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors actively accumulate tokens amidst high staking participation and anticipation of institutional payroll adoption. The community remains focused on key catalysts like the Clarity Act and the expansion of the SuperApp, viewing recent market dips as strategic entry points for long-term positioning.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.read more...

Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Moderate Buy" by Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has ass...

Cardiff Oncology (NASDAQ:CRDF) Trading Down 1.1% - Here's What Happened

Cardiff Oncology (NASDAQ:CRDF) Stock Price Down 1.1% - Here's Why...

Noble Financial Issues Optimistic Estimate for CRDF Earnings

Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Research analysts at Noble Financial raised their Q1 2026 earnings per share (EPS) estimates for shares of Cardiff Oncology in a note issued to...

Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat...

Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar

Cardiff Oncology (NASDAQ:CRDF) interim CEO Mani Mohindru outlined updated clinical results and development plans for the company's investigational PLK1 inhibitor onvansertib during a webinar focused...

What is Zacks Research's Forecast for CRDF FY2027 Earnings?

Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Investment analysts at Zacks Research lowered their FY2027 EPS estimates for Cardiff Oncology in a note issued to investors on Monday, March 2nd...

Cardiff Oncology (NASDAQ:CRDF) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Cardiff Oncology from a "sell" rating to a "hold" rating in a research note on Wednesday...

Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of "Moderate Buy" by Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat reports. One research analyst...

HC Wainwright Issues Optimistic Outlook for CRDF Earnings

Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 EPS estimates for Cardiff Oncology in a note issued to investors on Wednesday...

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The firm is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Cardiff Oncology Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.12	--	--	N/A
Q1 '26	-$0.13	-$0.18	-33.51%	MISSED
Q4 '25	-$0.19	-$0.11	41.80%	BEAT
Q3 '25	-$0.20	-$0.17	17.07%	BEAT
Q2 '25	-$0.19	-$0.21	-9.09%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

CRDFCardiff Oncology Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest CRDF News